leisure time -WSS

leisure time

author：explore 2025-09-29 21:14:33 - browse：284

Electrocardiogram in the shape of the United States map — Adobe

The market for artificial intelligence in health care is about as transparent as a brick wall. New tools achieve impressive results in published studies. But it is often difficult to compare them head to head with similar products, or tell whether they will work on different kinds of patients.

A new company is promising to change that — if it can convince AI developers to expose their products to more rigorous testing.

Called Dandelion Health, the New York-based firm is launching a first-of-its-kind public service to evaluate AI products on independent data designed to root out weaknesses and reveal bias. The company said Wednesday its initial pilot program, to begin next month, will focus on testing algorithms that use electrocardiograms to predict heart conditions.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： Hospitals look to new technology to keep health care workers safe

focus

WSS

Morphosys mixed study results for blood cancer drug

A daunting task: navigating dual Medicare, Medicaid eligibility

ThunderShirts, dance parties and anxiety meds can help ease dogs' July Fourth dread

US ambassador visits Wall Street Journal reporter detained in Russia on charges of espionage

ThunderShirts, dance parties and anxiety meds can help ease dogs' July Fourth dread

Readout Newsletter: Bayer study halts, Carmot to IPO, and more

knowledge

leisure time

focus

Alkermes shareholders re

Readout Newsletter: The latest at Gilead, Catalent, and the NIH

Alkermes shareholders re

CRISPR pioneers react to Casgevy, first gene

Peter Hotez and the public health issue of online harassment

Leon Gautier, last member of French D

Psychedelics group wrestles with new pharma identity

Buoyed by wins on obesity, Novo Nordisk eyes heart disease

DIEP, the 'gold standard' of breast reconstruction, is under threat

Churchill Downs extends trainer Bob Baffert's ban through 2024

hotspot

Anthos stroke drug appears safer than common blood thinner

Astellas still sees hope in its gene therapy after four deaths

Readout Newsletter: Bayer study halts, Carmot to IPO, and more

US judge blocks portions of new Florida elections law

PlayStation controller and acoustic messaging: How the missing Titanic tourist sub works

Anthos stroke drug appears safer than common blood thinner

focus

leisure time

leisure time

focus